logo-loader
viewFutura Medical PLC

Futura Medical begins recruitment for MED2002 safety trial

James Barder, chief executive of Futura Medical plc (LON:FUM), tells Proactive they've begun recruitment for a pharmacokinetic study of their lead product, MED2002.

It's a prelude to starting phase III trials of the breakthrough gel for erectile dysfunction.

Data from 40 men will determine the doses used in the final-stage clinical assessment, which will kick off as “soon as practicable” after the current programme.

Quick facts: Futura Medical PLC

Price: 33.5 GBX

AIM:FUM
Market: AIM
Market Cap: £68.56 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Futura Medical kicks off work on Phase III trial for erectile dysfunction gel

James Barder, chief executive of Futura Medical PLC (LON:FUM), tells Proactive they've begun preparatory work on the first Phase III efficacy trial for MED2002 - their topical gel for erectile dysfunction (ED). The study will recruit approximately 1,000 patients with mild, moderate and...

on 27/4/18

RNS

Holding(s) in Company

14 hours, 43 minutes ago

Holding(s) in Company

14 hours, 44 minutes ago

Holding(s) in Company

1 week, 3 days ago

Holding(s) in Company

3 weeks, 2 days ago

Change of Auditor

4 weeks, 1 day ago

2 min read